2 weeks Ago By ABMN Staff
Prudential Financial Inc. acquired a new stake in shares of Zymeworks Inc. ( NYSE:ZYME – Free Report ) during the 4th quarter, according to its most recent filing with the SEC.
The institutional investor acquired 19,660 shares of the company’s stock, valued at approximately $288,000. A number of other large investors also recently modified their holdings of the company. AlphaQuest LLC grew its position in Zymeworks by 480.
2% during the fourth quarter. AlphaQuest LLC now owns 2,808 shares of the company’s stock valued at $41,000 after acquiring an additional 2,324 shares during the last quarter. FMR LLC lifted its stake in Zymeworks by 84.
2% in the third quarter. FMR LLC now owns 3,336 shares of the company’s stock worth $42,000 after purchasing an additional 1,525 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in Zymeworks in the fourth quarter worth $151,000.
New York State Common Retirement Fund boosted its position in Zymeworks by 42.7% during the fourth quarter. New York State Common Retirement Fund now owns 13,371 shares of the company’s stock valued at $196,000 after buying an additional 4,000 shares during the period.
Finally, Teacher Retirement System of Texas increased its holdings in shares of Zymeworks by 19.2% in the fourth quarter. Teacher Retirement System of Texas now owns 13,743 shares of the company’s stock worth $201,000 after buying an additional 2,216 shares during the period.
92.89% of the stock is owned by hedge funds and other institutional investors. Insider Buying and Selling In other news, Director Ecor1 Capital, Llc purchased 196,438 shares of Zymeworks stock in a transaction that occurred on Friday, April 4th.
The shares were bought at an average cost of $11.17 per share, with a total value of $2,194,212.46.
Following the completion of the purchase, the director now directly owns 17,699,774 shares in the company, valued at approximately $197,706,475.58. This trade represents a 1.
12 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink . Insiders purchased a total of 1,409,296 shares of company stock valued at $17,125,418 over the last three months.
Corporate insiders own 1.92% of the company’s stock. Analysts Set New Price Targets View Our Latest Report on ZYME Zymeworks Trading Down 5.
6 % NYSE:ZYME opened at $9.44 on Friday. The company has a 50-day moving average price of $12.
75 and a 200-day moving average price of $13.58. The stock has a market cap of $656.
81 million, a price-to-earnings ratio of -6.29 and a beta of 1.18.
Zymeworks Inc. has a 12 month low of $7.97 and a 12 month high of $17.
70. About Zymeworks ( Free Report ) Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Featured Articles Want to see what other hedge funds are holding ZYME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zymeworks Inc. ( NYSE:ZYME – Free Report ).
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter ..
